Key result
Alpk2 overexpression prevents diastolic dysfunction in aged and HFpEF mice via TPM1 Ser283 phosphorylation.
Why the study?
Mechanisms underlying cardiac diastole remain elusive due to a historical focus on systolic dysfunction, leaving the pathophysiology of HFpEF unclear.
Does the cardiac-specific atypical protein kinase ALPK2 regulate cardiac diastolic dysfunction in preclinical models of aging and heart failure with preserved ejection fraction (HFpEF)?
Does the cardiac-specific atypical protein kinase ALPK2 regulate cardiac diastolic dysfunction in preclinical models of aging and heart failure with preserved ejection fraction (HFpEF)?
This preclinical study identifies the cardiac-specific atypical kinase ALPK2 as a key regulator of tropomyosin 1 phosphorylation and myocardial relaxation, offering a potential novel therapeutic target for diastolic dysfunction in HFpEF and cardiac aging.
Answers are grounded in this paper and cite their sources.
ALPK2 modulation may mitigate diastolic dysfunction in preclinical models; leaves open translation to human HFpEF therapies.
Protein phosphorylation, controlled by protein kinases, is central to regulating various pathophysiological processes, including cardiac systolic function. The dysregulation of protein kinase activity plays a significant role in the pathogenesis of cardiac systolic dysfunction. While cardiac contraction mechanisms are well documented, the mechanisms underlying cardiac diastole remain elusive. This gap persists owing to the historical focus on systolic dysfunction in heart failure research. Recently, heart failure with preserved ejection fraction (HFpEF), an age-related disease characterized by cardiac diastolic dysfunction, has emerged as a major public health concern. However, its underlying mechanism remains unclear. In this study, we investigated cardiac protein kinases by analyzing the gene expression of 518 protein kinases in human tissues. We identified alpha-kinase 2 (ALPK2) as a novel cardiac-specific atypical kinase and generated tamoxifen-inducible, cardiomyocyte-specific Alpk2-knockout mice and Alpk2-overexpressing mice. Alpk2 deficiency did not affect cardiac systolic dysfunction in the myocardial infarction model or the pressure-overload-induced heart failure model. Notably, cardiomyocyte-specific Alpk2 deficiency exacerbated cardiac diastolic dysfunction induced by aging and in the HFpEF model. Conversely, Alpk2 overexpression increased the phosphorylation of tropomyosin 1, a major regulator that binds myosin to actin, and mitigated cardiac stiffness in HFpEF. This study provides novel evidence that ALPK2 represents a potential therapeutic target for cardiac diastolic dysfunction in HFpEF and age-related cardiac impairments.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2024) studied Heart failure with preserved ejection fraction (HFpEF) and age-related cardiac diastolic dysfunction. Cardiomyocyte-specific Alpk2 knockout and Alpk2 overexpression vs. Wild-type / control littermate mice was evaluated on Cardiac diastolic function (mitral E/E' ratio, relaxation time constant [Tau], and slope of the end-diastolic pressure-volume relationship [EDPVR]) and tropomyosin 1 (TPM1) Ser283 phosphorylation (p=<0.0001). Alpk2 overexpression increased tropomyosin 1 Ser283 phosphorylation and prevented cardiac diastolic dysfunction (E/E', Tau, EDPVR) in aged and HFpEF mice, whereas Alpk2 deficiency exacerbated it.
Synapse has enriched 10 related papers. Consider them for comparative context: